Samsung Biologics Co.,Ltd.
207940.KSFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
3,410
Cost of Revenue
1,692
Gross Profit
1,718
Gross Margin
50.4%
Operating Income
990
Operating Margin
29.0%
Net Income
812
Net Margin
23.8%
EPS (Basic)
$18.00
EPS (Diluted)
$18.00
EBITDA
1,512
EBITDA Margin
44.3%
2023
12/31/2023
Revenue
2,771
Cost of Revenue
1,425
Gross Profit
1,346
Gross Margin
48.6%
Operating Income
835
Operating Margin
30.1%
Net Income
643
Net Margin
23.2%
EPS (Basic)
$14.00
EPS (Diluted)
$14.00
EBITDA
1,269
EBITDA Margin
45.8%
2022
12/31/2022
Revenue
2,251
Cost of Revenue
1,150
Gross Profit
1,101
Gross Margin
48.9%
Operating Income
738
Operating Margin
32.8%
Net Income
599
Net Margin
26.6%
EPS (Basic)
$13.00
EPS (Diluted)
$13.00
EBITDA
1,016
EBITDA Margin
45.1%
2021
12/31/2021
Revenue
1,176
Cost of Revenue
631
Gross Profit
545
Gross Margin
46.3%
Operating Income
403
Operating Margin
34.3%
Net Income
295
Net Margin
25.1%
EPS (Basic)
$7.00
EPS (Diluted)
$7.00
EBITDA
543
EBITDA Margin
46.2%
2020
12/31/2020
Revenue
874
Cost of Revenue
562
Gross Profit
312
Gross Margin
35.7%
Operating Income
220
Operating Margin
25.1%
Net Income
181
Net Margin
20.7%
EPS (Basic)
$4.00
EPS (Diluted)
$4.00
EBITDA
332
EBITDA Margin
38.0%